ES2516717T3 - Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo - Google Patents

Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo Download PDF

Info

Publication number
ES2516717T3
ES2516717T3 ES09779547.0T ES09779547T ES2516717T3 ES 2516717 T3 ES2516717 T3 ES 2516717T3 ES 09779547 T ES09779547 T ES 09779547T ES 2516717 T3 ES2516717 T3 ES 2516717T3
Authority
ES
Spain
Prior art keywords
renal failure
acute renal
risk
urine
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09779547.0T
Other languages
English (en)
Inventor
Yaremi Quiros Luis
Laura Ferreira Redondo
Sandra María SANCHO MARTÍNEZ
José Manuel González De Buitrago Arriero
Francisco José López Hernández
José Miguel López Novoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Salamanca
Original Assignee
Universidad de Salamanca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Salamanca filed Critical Universidad de Salamanca
Application granted granted Critical
Publication of ES2516717T3 publication Critical patent/ES2516717T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9446—Antibacterials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Metodo para proporcionar datos para determinar el riesgo de un individuo de desarrollar fallo renal agudo (FRA), o para determinar FRA, que comprende la deteccion y/o cuantificacion de una proteina al menos un 70% o 100% identica a la SEQ ID NO: 1, en una muestra biologica aislada de un individuo (sujeto), preferiblemente el individuo es un humano.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13

Claims (1)

  1. imagen1
ES09779547.0T 2009-05-26 2009-05-26 Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo Active ES2516717T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/056381 WO2010136059A1 (en) 2009-05-26 2009-05-26 Urinary gm2 activator protein as a marker of acute renal failure or the risk of developing acute renal failure

Publications (1)

Publication Number Publication Date
ES2516717T3 true ES2516717T3 (es) 2014-10-31

Family

ID=41134567

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09779547.0T Active ES2516717T3 (es) 2009-05-26 2009-05-26 Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo

Country Status (6)

Country Link
US (1) US20120129721A1 (es)
EP (1) EP2435826B1 (es)
JP (1) JP5736597B2 (es)
CA (1) CA2763496A1 (es)
ES (1) ES2516717T3 (es)
WO (1) WO2010136059A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531615A (ja) * 2009-07-02 2012-12-10 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 急性腎不全を診断するためのプロセス及びマーカー
RU2599099C1 (ru) * 2015-08-17 2016-10-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития острой почечной недостаточности по уровню экспрессии генов casp3, casp8 и casp9 после кратковременной ишемии почки
US11007253B2 (en) 2015-12-18 2021-05-18 Talengen International Limited Method for preventing or treating radiation and chemical damage
US20190328848A1 (en) * 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating drug-induced renal injury
JP7262457B2 (ja) * 2017-11-08 2023-04-21 テトラ ラバル ホールディングス アンド ファイナンス エス エイ 食品バッチの微生物学的リスクレベルを決定する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
WO2003092601A2 (en) * 2002-04-30 2003-11-13 Seikagaku Corporation A method for detecting lysosomal storage diseases
FR2864086A1 (fr) * 2003-12-23 2005-06-24 Biomerieux Sa Facteur cytotoxique isole associe a la sclerose en plaques et procede de detection dudit facteur cytotoxique
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury

Also Published As

Publication number Publication date
JP5736597B2 (ja) 2015-06-17
US20120129721A1 (en) 2012-05-24
EP2435826A1 (en) 2012-04-04
WO2010136059A1 (en) 2010-12-02
EP2435826B1 (en) 2014-05-21
JP2012528300A (ja) 2012-11-12
CA2763496A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
ES2516717T3 (es) Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo
Bakos et al. Developmental toxicity and estrogenic potency of zearalenone in zebrafish (Danio rerio)
Wang et al. Development of aquatic life criteria for triclosan and comparison of the sensitivity between native and non-native species
CL2013002907A1 (es) Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; y uso para reducir los niveles de proteina viral en una celula de un animal (div.sol.n°822-12).
ECSP088586A (es) Composición de la garrapata incluyendo las garrapatas glycyphagidae y phytoseiid, su utilización, método de crianza de la garrapata depredadora phytoseiid, sistema de crianza para la mencionada garrapata depredadora phytoseiid y métodos para control
ES2484142T3 (es) Diagnóstico molecular y clasificación del melanoma maligno
FR2912600B1 (fr) Methode et systeme de retassage d'un plateau d'oeufs
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
EA200701427A1 (ru) Композиция клещей, её применение, способ разведения хищного клеща - фитосейида, система для разведения указанного хищного клеща - фитосейида и способы биологического контроля вредителей в культуре
Manerikar et al. In vitro and in vivo genotoxicity assessment of Cr (VI) using comet assay in earthworm coelomocytes
Brockmeier et al. Effects of 17β-trenbolone on Eastern and Western mosquitofish (Gambusia holbrooki and G. affinis) anal fin growth and gene expression patterns
BR112012013362A2 (pt) sistema para a determinação de um valor para pelo menos um parâmetro que descreve a atividade microbiana de organismos biológicos individuais em uma amostra de líquido, e, método para a determinação da atividade microbiana em uma amostra de líquido
CY1119262T1 (el) Αναλυτικες μεθοδοι και συστοιχιες για χρηση στην ταυτοποιηση παραγοντων που επαγουν ευαισθητοποιηση στο ανθρωπινο δερμα
CL2010000720A1 (es) Método para la evaluar la respuesta a la inhibición de her en una muestra de paciente, que comprende detectar la proteina marcadora egf (div.sol.no. 1240-06).
AR051523A1 (es) Metodo para medir la resistencia o sensibilidad a docetaxel
EP2520935A3 (en) Organ-specific proteins and methods of their use
PE20131062A1 (es) Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
BRPI0916624A2 (pt) anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
Mabrouk et al. Fluctuating asymmetry in grass goby Zosterisessor ophiocephalus Pallas, 1811 inhabiting polluted and unpolluted area in Tunisia
Wang et al. The effect of fluorine exposure on morphological indicators and intestinal microbial community in Bufo gargarizans tadpoles
ES2530567T3 (es) Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
Podgorniak et al. Differences in brain gene transcription profiles advocate for an important role of cognitive function in upstream migration and water obstacles crossing in European eel